| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ... Science translational medicine 9 (399), eaaa0984, 2017 | 1191 | 2017 |
| Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and … H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash, TE Donegan, ... Journal of clinical oncology 29 (3), 330, 2011 | 616 | 2011 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 596 | 2019 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 562 | 2015 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 491 | 2014 |
| Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Science translational medicine 7 (275), 275ra22-275ra22, 2015 | 446 | 2015 |
| Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment S Müller, G Kohanbash, SJ Liu, B Alvarado, D Carrera, A Bhaduri, ... Genome biology 18, 1-14, 2017 | 434 | 2017 |
| COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor CellsCOX-2 Blockade and Gliomagenesis M Fujita, G Kohanbash, W Fellows-Mayle, RL Hamilton, Y Komohara, ... Cancer research 71 (7), 2664-2674, 2011 | 385 | 2011 |
| Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas G Kohanbash, DA Carrera, S Shrivastav, BJ Ahn, N Jahan, T Mazor, ... The Journal of clinical investigation 127 (4), 1425-1437, 2017 | 290 | 2017 |
| Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models X Zhu, F Nishimura, K Sasaki, M Fujita, JE Dusak, J Eguchi, ... Journal of translational medicine 5, 1-15, 2007 | 205 | 2007 |
| Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 R Ueda, G Kohanbash, K Sasaki, M Fujita, X Zhu, ER Kastenhuber, ... Proceedings of the National Academy of Sciences 106 (26), 10746-10751, 2009 | 195 | 2009 |
| Immunotherapeutic approaches for glioma H Okada, G Kohanbash, X Zhu, ER Kastenhuber, A Hoji, R Ueda, M Fujita Critical Reviews™ in Immunology 29 (1), 2009 | 189 | 2009 |
| STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor MicroenvironmentSTING-Mediated Antiglioma Immunity T Ohkuri, A Ghosh, A Kosaka, J Zhu, M Ikeura, M David, SC Watkins, ... Cancer immunology research 2 (12), 1199-1208, 2014 | 186 | 2014 |
| Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and … IF Pollack, RI Jakacki, LH Butterfield, RL Hamilton, A Panigrahy, ... Journal of Clinical Oncology 32 (19), 2050, 2014 | 183 | 2014 |
| GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-αIL-4Rα+ Suppressive Myeloid Cells in Gliomas G Kohanbash, K McKaveney, M Sakaki, R Ueda, AH Mintz, N Amankulor, ... Cancer research 73 (21), 6413-6423, 2013 | 182 | 2013 |
| Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy ZS Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ... Journal of Experimental Medicine 215 (1), 141-157, 2018 | 176 | 2018 |
| Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy X Zhu, M Fujita, LA Snyder, H Okada Journal of neuro-oncology 104, 83-92, 2011 | 174 | 2011 |
| Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell–based therapeutics JG Zhang, J Eguchi, CA Kruse, GG Gomez, H Fakhrai, S Schroter, W Ma, ... Clinical Cancer Research 13 (2), 566-575, 2007 | 172 | 2007 |
| Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly … T Tatsumi, J Huang, WE Gooding, A Gambotto, PD Robbins, ... Cancer research 63 (19), 6378-6386, 2003 | 171 | 2003 |
| EphA2 as a glioma-associated antigen: a novel target for glioma vaccines M Hatano, J Eguchi, T Tatsumi, N Kuwashima, JE Dusak, MS Kinch, ... Neoplasia 7 (8), 717-722, 2005 | 169 | 2005 |
